SOX2 and neoplasm: Consistent with the results from PHB deletion in GSC-derived xenografts, RocA treatment resulted in a dramatic increase in ROS levels, a reduction in SOX2+ tumor cells, and an increase in cell death in tumors (Fig. 6k and Supplementary Fig. 8d).